ClinicalTrials.gg
CompletedNCT02300259Updated Jun 26, 2020Results posted

A Study of LY2623091 in Healthy Participants

A Phase 1 interventional study of LY2623091 and Itraconazole in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The first purpose of this study is to evaluate the effect of itraconazole (and possibly diltiazem) on the amount of LY2623091 in the blood stream and how long the body takes to get rid of it.

The second purpose of the study is to evaluate the effect of LY2623091 on the amount of simvastatin (and possibly tadalafil) in the blood stream and how long the body takes to get rid of it.

The safety and tolerability of LY2623091 when given with itraconazole, simvastatin and diltiazem or tadalafil will be evaluated.

There will be three groups of participants in this study. Results from Groups 1 and 2 will be analyzed during the study to determine whether to enroll participants in Group 3 or 4. The study is expected to last up to 40 days from the first dose to follow-up (inclusive). Screening may occur up to 28 days prior to enrollment.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants as determined by medical history, physical examination, clinical laboratory tests, and (ECGs).
  • Have a (BMI) between 18 and 32.0 kilograms per square meter (kg/m\^2) inclusive, at screening
  • Female participants must be of non-

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    LY2623091 (Group 1)

    LY2623091 administered orally once on Day 1 of Period 1.

    Drug: LY2623091

  • Experimental
    Itraconazole + LY2623091 (Group 1)

    200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.

    Drug: LY2623091 · Drug: Itraconazole

  • Experimental
    Simvastatin (Group 2)

    20 mg simvastatin administered orally once daily on Day 1.

    Drug: Simvastatin

  • Experimental
    LY2623091 + Simvastatin (Group 2)

    LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.

    Drug: LY2623091 · Drug: Simvastatin

  • Experimental
    Tadalafil (Group 3)

    5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.

    Drug: Tadalafil

  • Experimental
    Tadalafil + LY2623091 (Group 3)

    LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.

    Drug: LY2623091 · Drug: Tadalafil

  • Experimental
    LY2623091 (Group 4)

    LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.

    Drug: LY2623091

  • Experimental
    Diltiazem + LY2623091 (Group 4)

    240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.

    Drug: LY2623091 · Drug: Diltiazem

Interventions

  • Administered orally

  • DrugItraconazole

    Administered orally

  • Administered orally

  • Administered orally

  • DrugDiltiazem

    Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091

    Time frame: Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose

  2. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY2623091

    Time frame: Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose

  3. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY2623091

    Time frame: Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose

  4. Pharmacokinetics: Maximum Drug Concentration (Cmax) of Simvastatin and Simvastatin Acid

    Time frame: Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose

  5. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of Simvastatin and Simvastatin Acid

    Time frame: Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose

  6. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Simvastatin and Simvastatin Acid

    Time frame: Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose

07

Results

Posted Jun 26, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneLY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)
Started161616
Received at least one dose of study drug161616
Completed161614
Not completed002
Withdrew: Adverse event001
Withdrew: Withdrawal by subject001
Period 2
Participant flow — Period 2
MilestoneLY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)
Started16014
Completed15013
Not completed101
Withdrew: Adverse event100
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091
Time frame:
Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091
nanograms per milliliter (ng/mL)LY2623091 (Group 1)Itraconazole + LY2623091 (Group 1)LY2623091 (Group 4)Diltiazem + LY2623091 (Group 4)
Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY262309161.9 ± 2166.9 ± 2761.8 ± 3464.2 ± 30
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY2623091
Time frame:
Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY2623091
nanograms*hour/milliliter (ng*h/mL)LY2623091 (Group 1)Itraconazole + LY2623091 (Group 1)LY2623091 (Group 4)Diltiazem + LY2623091 (Group 4)
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY26230912540 ± 275660 ± 312390 ± 393360 ± 43
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY2623091
Time frame:
Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose
Reported as:
Geometric mean · ng*hr/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY2623091
ng*hr/mLLY2623091 (Group 1)Itraconazole + LY2623091 (Group 1)LY2623091 (Group 4)Diltiazem + LY2623091 (Group 4)
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY26230912480 ± 275240 ± 312340 ± 393130 ± 40
PrimaryPharmacokinetics: Maximum Drug Concentration (Cmax) of Simvastatin and Simvastatin Acid
Time frame:
Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Drug Concentration (Cmax) of Simvastatin and Simvastatin Acid
ng/mLSimvastatin (Group 2)LY2623091 + Simvastatin (Group 2)
Simvastatin7.78 ± 639.89 ± 45
Simvastatin Acid0.720 ± 410.877 ± 55
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of Simvastatin and Simvastatin Acid
Time frame:
Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of Simvastatin and Simvastatin Acid
ng*h/mLSimvastatin (Group 2)LY2623091 + Simvastatin
Simvastatin17.4 ± 4824.1 ± 34
Simvastatin Acid7.15 ± 568.88 ± 77
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Simvastatin and Simvastatin Acid
Time frame:
Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Simvastatin and Simvastatin Acid
ng*hr/mLSimvastatin (Group 2)LY2623091 + Simvastatin
Simvastatin16.5 ± 4923.0 ± 34
Simvastatin Acid5.42 ± 486.87 ± 87

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2623091 (Group 1)—0/16 (0%)0/16 (0%)
Itraconazole (Group 1)—0/16 (0%)3/16 (18.8%)
Itraconazole + LY2623091 (Group 1)—0/16 (0%)6/16 (37.5%)
Simvastatin (Group 2)—0/16 (0%)0/16 (0%)
LY2623091 (Group 2)—0/16 (0%)4/16 (25%)
LY2623091 + Simvastatin (Group 2)—0/16 (0%)1/16 (6.3%)
LY2623091 (Group 4)—0/16 (0%)3/16 (18.8%)
Diltiazem (Group 4)—0/14 (0%)1/14 (7.1%)
Diltiazem + LY2623091 (Group 4)—0/14 (0%)1/14 (7.1%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventLY2623091 (Group 1)Itraconazole (Group 1)Itraconazole + LY2623091 (Group 1)Simvastatin (Group 2)LY2623091 (Group 2)LY2623091 + Simvastatin (Group 2)LY2623091 (Group 4)Diltiazem (Group 4)Diltiazem + LY2623091 (Group 4)
Lacrimation increasedEye disorders0/160/162/160/160/160/160/160/140/14
ConstipationGastrointestinal disorders0/160/160/160/162/160/161/161/140/14
DiarrhoeaGastrointestinal disorders0/162/161/160/160/160/160/160/140/14
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/160/162/160/160/160/160/160/140/14
Night sweatsSkin and subcutaneous tissue disorders0/160/162/160/160/160/160/160/140/14
Abdominal distensionGastrointestinal disorders0/161/160/160/160/160/160/161/140/14
Abdominal painGastrointestinal disorders0/160/160/160/160/160/160/161/140/14
Aspartate aminotransferase increasedInvestigations0/160/160/160/160/160/160/160/141/14
Abdominal discomfortGastrointestinal disorders0/161/161/160/160/160/160/160/140/14
CheilitisGastrointestinal disorders0/160/160/160/160/161/160/160/140/14

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)LY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)Total
Mean42.1 ± 9.437.8 ± 10.139.2 ± 9.339.7 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)LY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)Total
Female42713
Male1214935
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)Total
Hispanic or Latino98825
Not Hispanic or Latino78823
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American55616
White1091029
More than one race1203
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)LY2623091 + Itraconazole (Group 1)Simvastatin + LY2623091 (Group 2)LY2623091 + Diltiazem (Group 4)Total
United States16161648
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2020, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Nov 24, 2014
Start
Nov 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Jun 26, 2020
Last update
Jun 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02300259
Responsible party
Sponsor
First posted
Nov 24, 2014
Start date
Nov 2014
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Jun 26, 2020
Last update
Jun 26, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LY-2623091 · Simvastatin · Tadalafil

Start the discussion